Volume | 16,258 |
|
|||||
News | (1) | ||||||
Day High | 3.33 | Low High |
|||||
Day Low | 3.0301 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Chromocell Therapeutics Corporation | CHRO | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.32 | 3.0301 | 3.33 | 3.13 | 3.31 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
492 | 16,258 | $ 3.22 | $ 52,271 | - | 3.0301 - 6.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:30:00 | 100 | $ 3.13 | USD |
Chromocell Therapeutics Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 18.05M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Chromocell Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CHRO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.50 | 3.68 | 3.0301 | 3.40 | 19,983 | -0.37 | -10.57% |
1 Month | 4.27 | 4.84 | 3.0301 | 3.75 | 20,085 | -1.14 | -26.70% |
3 Months | 6.00 | 6.00 | 3.0301 | 4.14 | 30,098 | -2.87 | -47.83% |
6 Months | 6.00 | 6.00 | 3.0301 | 4.14 | 30,098 | -2.87 | -47.83% |
1 Year | 6.00 | 6.00 | 3.0301 | 4.14 | 30,098 | -2.87 | -47.83% |
3 Years | 6.00 | 6.00 | 3.0301 | 4.14 | 30,098 | -2.87 | -47.83% |
5 Years | 6.00 | 6.00 | 3.0301 | 4.14 | 30,098 | -2.87 | -47.83% |
Chromocell Therapeutics Description
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. |